Company intelligence / Profile preview
DermBiont, Inc.
Boston, Massachusetts, United States
- Ownership
- Private
- Employees
- ~103
- Development stage
- Other
01
Overview
DermBiont has shown positive Phase 2 trial data with SM-020 for seborrheic keratoses and SM-030 for melasma, achieving higher efficacy compared to current treatments like hydroquinone. SM-020 has shown over 80% response in lesions treated, with over 50% of lesions completely cleared in the most effective dosing regimen[1].
- Therapeutic areas
- Dermatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on DermBiont, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DermBiont, Inc..